AMR were treated with 6-9 sessions of plasmapheresis with intravenous immunoglobulin (IVIG; 1 3 5 100 mg/kg) in conjunction with intravenous methylprednisolone 500 mg administered once daily 1 3 6 for 3 days. In selected cases, additional drug therapy with rituximab or bortezomib was instituted 1 3 7 based upon clinical response. The details of antibody testing performed at our center have been described previously 1 3 9 (14). Briefly, pre-transplant complement-dependent cytotoxicity (CDC) assays and three-color Platform). Results of bead assays were measured as MFI. For highly sensitized patients an MFI 1 4 5 of >5,000 and for de-novo kidney transplant recipients an MFI >10,000 was considered 1 4 6 unacceptable for routine transplantation. Calculated Panel Reactive Antibody (cPRA) was 1 4 7 determined using the OPTN calculator from the following url: 160 µL of water. After centrifugation for 2 minutes at 12,300 rpm, 350 µL of supernatant was 1 5 6 transferred to auto sampler vials and dried under vacuum. Dried extracts were re-suspended 1 5 7 using 110 µL of a methanol:toluene (10:1, v/v) mixture containing CUDA (12- phase B: 10 mM ammonium acetate (pH 8) in 50% ACN. Gradient (B%) ramps from 0.1 to 20 in 1 6 3 10 mins; rises to 98 at 11 min, keeps for 2 mins, then drops back to 0.1 and maintains for 3 mins. parameters were created with a stepwise forward method ( Fig. 1 ). Regression performance was 1 7 0 estimated with R 2 , misclassification error and area under the ROC Curve (AUC). Estimates were 1 7 1 validated with bootstrap coefficient interval ( Fig. 1 ). Predictors combined model was cross 1 7 2 validated with Random Forest method, and the misclassification out-of-bag error (OOB error) 1 7 3 was estimated and compared to the RLDA error for validation ( Fig. 1 ). Changes over time were 1 7 4 also estimated using the sparse partial least square method and separation of the groups was 1 7 5 validated with a permutation test. A t-test was used to compare two time points within a group Demographic comparison of the two groups prior to transplantation is shown in Table 1 .
Patients in the AMR group were more likely to be female, re-transplants and had a higher degree 1 8 2 of sensitization (higher cPRA) and presence of donor specific antibody (higher DSA) at the time 1 8 3 of transplant. They were also more likely to have hyperlipidemia. There were no differences 1 8 4 noted for age, race, weight, years on dialysis, type of dialysis, delayed graft function, or the 1 8 5 presence or absence of diabetes mellitus. differences between SC and AMR (Fig. 2) . The concentration of phosphatidylcholine (PC) was 1 8 8 significantly diminished in AMR, while there was a trend for an increased concentration of 1 8 9 lysophosphatidylcholine (LPC). The AMR group also showed a significantly lower 1 9 0 concentration of phosphatidylethanolamine (PE), lysophosphatidylethanolamine (LPE), (PLA 2 ) as a signal of increased metabolism was assessed by the ratio of PL to lysophospholipids 1 9 5 (LPL). The AMR group showed decreased ratios of PC/LPC and PE/LPE indicating higher 1 9 6 activity of PLA 2 at T1. PL degradation, evident for PE, was higher in the AMR group compared to the SC group. . Preliminary data demonstrated that there are significant differences in the pre-transplant 2 0 2 lipidome between SC and AMR. This led to the hypothesis that the T1 lipidome or some of lipids alone, clinical data alone, and a merged lipid and clinical data to test for prediction 2 0 7 accuracy ( Table 2 ). The analysis identified seven distinct lipids that discriminated between AMR Further comparison of the four lipids predictors of kidney rejection showed that these 2 1 5 lipids are significantly decreased in AMR compared to the SC group. In the PC (18:0 /20:4) plot, 2 1 6 it is possible to notice the presence of outliers in both groups (Fig. 4A ). Random Forest method training, using the entire study population, the addition of these two lipids takes the model 2 2 4 estimation from R 2 =0.75 to R 2 =0.81. Following the identification of the lipid differences at T1 and their ability to predict graft Fig. 5A ). However, for the subsequent times from 6 months to 12 months, there was no 2 3 6 significant change in the lipidomic profile. This finding suggests that stabilization of the lipid 2 3 7 changes after transplant is associated with the achievement of improved kidney function and 2 3 8 possibly a reduced milieu of inflammation (Fig. 5B) . The data was subjected to validation using 2 3 9 the permutation test ( Fig. 5C ) and showed a statistically significant metabolic difference (p= 2 4 0 0.034) from T1 to 6 months after transplantation. pre-rejection and post-rejection compared to T1 (Fig. 7a ). While a slight change was observed 2 5 0 from T1 to post-rejection ( Fig. 7B ), validation analysis using permutation testing demonstrated 2 5 1 this difference to be non-significant (p=0.869) (Fig. 7C) . These findings indicate that in contrast As our data revealed that there were significant T1 vs T2 lipid differences between SC, 2 5 8 but not in AMR, we further investigated the data to identify the exact differences in the lipidome 2 5 9 between SC and AMR at T2. Any differences identified would indicate an alteration in the lipid 2 6 0 metabolic environment at the time of rejection that would distinguish AMR from SC. Since there 2 6 1 were no significant differences between T2 and T3 for SC group we chose to use SC at T2 (6 2 6 2 months post-transplant) to compare with AMT at T2 (time of AMR). The analysis revealed a 2 6 3 panel of 13 lipids that were found to differentiate the two groups at T2 (Fig. 8 ). As noted 2 6 4 previously, these 13 lipids were again comprised of LPE and PC species containing confirms the presence of a sustained lipid metabolic difference between SC and AMR over time that distinguish these two groups of patients. In this first study, we report novel data that the lipidome could be used to identify kidney 2 7 2 transplant patients with a higher risk of antibody-mediated rejection at the time of transplant. In kidney disease and hemodialysis in selected groups of patients compared with others(15). suggested (20, 21) . In our study, although both groups represent patients who had CKD 2 9 6 progression, the SC group had higher PC and LPE than the AMR group and a trend for lower 2 9 7 LPC suggesting that subpopulations with varying degrees of inflammatory milieu might exist LPC has being associated with pro-inflammatory effects (22), but there is not much oxidation is primarily due to PLA 2 activity rather than by hypochlorous acid generated by 3 0 4 myeloperoxidase, while LPC can be generated from both processes(23). The dual effect of PLA 2 3 0 5 is well known by its pro-inflammatory action in hydrolysis of PC to produce LPC promoting 3 0 6 atherogenesis, as well as its anti-inflammatory action in hydrolysis of platelet-activating factor 3 0 7 (PAF) and oxidized PLs(24). This suggest that processes that are not directly related to oxidative 3 0 8 stress generate LPE in CKD patients. The activity of PLA 2 in our study was assessed by the ratio 3 0 9 of PL to LPL. The AMR group had a higher PLA 2 activity, especially for degradation of PE to 3 1 0 produce LPE. The PC/LPC ratio, as an inflammatory marker is also indirectly represented by the 3 1 1 increased activity of PLA 2 in inflammatory diseases (25, 26) . It has been reported that in vitro LPE induces activation of the mitogen-activated protein A-induced peritonitis demonstrated a vast anti-inflammatory action. In that study LPE- Our results suggest that the lack of anti-inflammatory protection in patients on the day of the onset of rejection, confirming that the metabolic profile at T1 predicting AMR persisted after 3 2 5 transplantation. Accordingly, over time comparison of SC and AMR showed that the difference 3 2 6 in LPE and PC levels were sustained after 6 months representing the metabolic difference 3 2 7 between rejection and non-rejection. The presence of monounsaturated and polyunsaturated fatty 3 2 8 acids in PL is also an indication that their low plasma content is a risk factor for kidney health There are some limitations to our study. Demographic comparisons between the SC and 3 3 5 AMR groups at T1 revealed that female gender, re-transplant, cPRA, DSA, and hyperlipidemia 3 3 6
were statistically more likely to be present in the AMR group. Moreover, we found DSA as the DSA and female gender were risk factors for AMR (33). Thus, the two groups could have been inherently different biochemically. Future larger studies with an increased sample size would be 3 4 0 need to confirm this preliminary study. Our finding of hyperlipidemia in AMR group could be 3 4 1 linked to the fact that hyperlipidemia is the most common form of dyslipidemia, a common Our study for the first time identifies the pre-transplant, post-transplant, and pre-rejection Following prospective validation in a larger cohort, these findings have the potential to alter the There are no conflicts of interest to report for any of the authors. shows that DSA is the more important predictor, followed by LPE (16:0) and PC (18:0/20:4) and year post-transplant, after a metabolic shift from T1 to T2. B) The lipid difference is highlighted 4 1 2 by the change in the first 6 months. C) Permutation test was performed as a validation test to 4 1 3 evaluate the statistical significance of the PLS-DA model separation from T1 to T2 (p=0.034).
1 4
Ellipses represent the 95%CI for each time point. The levels of the 19 different lipids that are significantly elevated 6 months after transplantation 4 1 8 are mostly comprised from the LPC class containing both unsaturated and saturated fatty acids. metabolic difference from T1 to T2 highlights the overlap of the 95% CI of the two time points. 
